CN102249951A - Aminophenyl ketone compound and application thereof in preparing antipsychotic drugs - Google Patents
Aminophenyl ketone compound and application thereof in preparing antipsychotic drugs Download PDFInfo
- Publication number
- CN102249951A CN102249951A CN2010101785769A CN201010178576A CN102249951A CN 102249951 A CN102249951 A CN 102249951A CN 2010101785769 A CN2010101785769 A CN 2010101785769A CN 201010178576 A CN201010178576 A CN 201010178576A CN 102249951 A CN102249951 A CN 102249951A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- alkyl
- fluorine
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to an aminophenyl ketone compound capable of selectively targeting dopamine receptors and nicotinic cholinergic receptors. Simultaneously, the aminophenyl ketone compound is a selective norepinephrine reuptake inhibitor, has high selective effects on norepinephrine transporter, can selectively inhibit presynaptic norepinephrine transport protein, strengthen the inverse effect of norepinephrine, and prolong the activity of norepinephrine released in the synaptic cleft, with low affinity and small influence for other neurotransmitter transporters and acceptors. Therefore, the compound and medicinal compositions containing the compound can be used for improving and/or treating indications such as depression, anxiety depression and cognitive defects, and can be used for helping people stop smoking.
Description
Technical field
The present invention relates to amino-benzene ketone compounds and they in the preparation psychosis medicine purposes in the dysthymia disorders medicine particularly.
Background technology
Dopamine HCL is present in maincenter and peripheral tissues widely as the 3rd acacatechin amine neurotransmitter, and is synthesized at the different sites of maincenter and peripheral tissues.Dopamine Receptors can be divided into D1 and two families of D2; Wherein D1 family comprises D1 and two hypotypes of D5, but its activated adenyl cyclase; D2 family comprises D2, D3 and three hypotypes of D4.Dopamine Receptors plays a major role in the effect of intermediary's antipsychotic drug.
Nicotine cholinergic receptor (Nicotinic acetylcholine receptor) is an ion gate channel-style acceptor, mainly is distributed on ganglion cell film and the Skeletal Muscle Cell film.The nAChR antagonist action plays an important role aspect nerve excitability in its acceptor.
Summary of the invention
Technical problem to be solved by this invention provides the amino-benzene ketone compounds of a kind of optionally target Dopamine Receptors, nicotine cholinergic receptor.
For solving above technical problem, the present invention takes following technical scheme:
Compound with logical formula I:
In the formula I:
R
01, R
02, R
03, R
04, R
05, R
06, R
07, R
08, R
09, be hydrogen or deuterium independently;
R
NFor being selected from a kind of in the following groups:
OH、CH
2Ra、OCH
2Ra、CORc、CHRdRi、(CH
2)nRj、
Wherein:
Ra represents H; C1～C5 alkyl; C1～C8 alkyl that one or more fluorine atoms replace; Phenyl, it is perhaps replaced by one or more groups that are selected from fluorine, chlorine, bromine, C1～C6 alkoxyl group, C1～C6 sulfydryl, C1～C6 amido for not replacing; Perhaps pyridyl, it is perhaps replaced by one or more groups that are selected from fluorine, chlorine, bromine, C1～C6 alkoxyl group, C1～C6 sulfydryl, C1～C6 amido for replacing;
Rc represents H, CH
2Ra, OCH
2Ra, C2～C12 secondary amine, CHRd (NHRe), NReCHRd (COORg), 2-furyl, 1-connection hexahydropyridine base or 1-morpholinyl;
Rd is H or C1～C6 alkyl;
Re is H, CH
2Rf, C1～C7 carbonyl or C1～C7 ester group;
Rg represents H or CH
2Rf;
Rf represents C1～C5 alkyl; C1～C8 alkyl that one or more fluorine atoms replace; Phenyl, it is perhaps replaced by one or more groups that are selected from fluorine, chlorine, bromine, C1～C6 alkoxyl group, C1～C6 sulfydryl, C1～C6 amido for not replacing; Perhaps Rf represents pyridyl, and it is perhaps replaced by one or more groups that are selected from fluorine, chlorine, bromine, C1～C6 alkoxyl group, C1～C6 sulfydryl, C1～C6 amido for not replacing;
Ri represents NReCHRd (COORg), OCOCHRd (NHRe) or OCOORg;
Rj represents 2-furyl, 1-connection hexahydropyridine base or 1-morpholinyl;
N is the integer between 1～6, and Y represents C1～C6 alkyl.
According to the present invention, n is preferably 2 or 3.
According to the present invention, representational compound has the compound of formula II, formula III, formula IV, formula (V), formula VI, formula (VII) and formula (VIII) expression.
According to the present invention, described pharmacologically acceptable salt includes but not limited to hydrochloride, phosphoric acid salt, vitriol, acetate, maleate, benzene sulfonate, toluenesulfonate, fumarate, tartrate etc.
Because the enforcement of above technical scheme, the present invention compared with prior art has following advantage:
Amino-benzene ketone compounds of the present invention is target Dopamine Receptors and nicotine cholinergic receptor optionally.Simultaneously, amino-benzene ketone compounds of the present invention still is the selectivity NRI, it has the selectively acting of height to the noradrenaline transporter body, can selectivity suppress ground presynaptic norepinephrine transporter, strengthen the upset effect of noradrenaline rope, the activity of the norepinephrine that prolongation discharges at synaptic cleft, and lower to the avidity of other neurotransmitter transporter and acceptor, influence little.Therefore, the present invention and comprise that pharmaceutical composition of the present invention can be used for improving and/or indications such as treatment dysthymia disorders, anxiety-depression, cognitive defect, and can be used for helping smoking cessation.
Embodiment
The present invention will be further described in detail below in conjunction with specific embodiment, but the present invention is not limited to following examples.
Embodiment 1
The compound that present embodiment provides a kind of formula II to represent:
Embodiment 2
The compound that present embodiment provides a kind of formula III to represent:
Embodiment 3
The compound that present embodiment provides a kind of formula IV to represent:
Embodiment 4
Present embodiment provides the compound of a kind of formula (V) expression:
Embodiment 5
The compound that present embodiment provides a kind of formula VI to represent:
Embodiment 6
Present embodiment provides the compound of a kind of formula (VII) expression:
Embodiment 7
Present embodiment provides the compound of a kind of formula (VII) expression:
Claims (6)
1. the compound and the pharmacologically acceptable salt thereof that have logical formula I:
In the formula I:
R
01, R
02, R
03, R
04, R
05, R
06, R
07, R
08, R
09, be hydrogen or deuterium independently;
R
NFor being selected from a kind of in the following groups:
OH、CH
2Ra、OCH
2Ra、CORc、CHRdRi、(CH
2)nRj、
And
Wherein:
Ra represents H; C1～C5 alkyl; C1～C8 alkyl that one or more fluorine atoms replace; Phenyl, it is perhaps replaced by one or more groups that are selected from fluorine, chlorine, bromine, C1～C6 alkoxyl group, C1～C6 sulfydryl, C1～C6 amido for not replacing; Perhaps pyridyl, it is perhaps replaced by one or more groups that are selected from fluorine, chlorine, bromine, C1～C6 alkoxyl group, C1～C6 sulfydryl, C1～C6 amido for replacing;
Rc represents H, CH
2Ra, OCH
2Ra, C2～C12 secondary amine, CHRd (NHRe), NReCHRd (COORg), 2-furyl, 1-connection hexahydropyridine base or 1-morpholinyl;
Rd is H or C1～C6 alkyl;
Re is H, CH
2Rf, C1～C7 carbonyl or C1～C7 ester group;
Rg represents H or CH
2Rf;
Rf represents C1～C5 alkyl; C1～C8 alkyl that one or more fluorine atoms replace; Phenyl, it is perhaps replaced by one or more groups that are selected from fluorine, chlorine, bromine, C1～C6 alkoxyl group, C1～C6 sulfydryl, C1～C6 amido for not replacing; Perhaps Rf represents pyridyl, and it is perhaps replaced by one or more groups that are selected from fluorine, chlorine, bromine, C1～C6 alkoxyl group, C1～C6 sulfydryl, C1～C6 amido for not replacing;
Ri represents NReCHRd (COORg), OCOCHRd (NHRe) or OCOORg;
Rj represents 2-furyl, 1-connection hexahydropyridine base or 1-morpholinyl;
N is the integer between 1～6, and Y represents C1～C6 alkyl.
2. compound according to claim 1 and pharmacologically acceptable salt thereof is characterized in that: described n is 2 or 3.
3. compound according to claim 1 and pharmacologically acceptable salt thereof is characterized in that: described compound is a kind of in the compound of formula II, formula III, formula IV, formula (V), formula VI, formula (VII) and formula (VIII) expression.
4. but described compound of claim 1 and drug salts thereof the purposes in preparation psychosis medicine.
5. purposes according to claim 4 is characterized in that: described psychosis medicine is for improving and/or treat the medicine of dysthymia disorders, anxiety-depression, cognitive defect.
But described compound of claim 1 and drug salts thereof the preparation aiding smoking cessation medicine in purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101785769A CN102249951A (en) | 2010-05-21 | 2010-05-21 | Aminophenyl ketone compound and application thereof in preparing antipsychotic drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101785769A CN102249951A (en) | 2010-05-21 | 2010-05-21 | Aminophenyl ketone compound and application thereof in preparing antipsychotic drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102249951A true CN102249951A (en) | 2011-11-23 |
Family
ID=44977564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101785769A Pending CN102249951A (en) | 2010-05-21 | 2010-05-21 | Aminophenyl ketone compound and application thereof in preparing antipsychotic drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102249951A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4393078A (en) * | 1982-03-15 | 1983-07-12 | Burroughs Wellcome Co. | Bupropion and ethanol |
| US20070015572A1 (en) * | 2000-10-05 | 2007-01-18 | Igt | Gaming device having a weighted probability for selecting a bonus game |
| US20070155729A1 (en) * | 2006-01-03 | 2007-07-05 | Algebra, Inc. | Therapeutic amine-arylsulfonamide conjugate compounds |
| CN101088985A (en) * | 2007-07-06 | 2007-12-19 | 浙江普洛医药科技有限公司 | Amfebutamone hydrochloride synthesizing process |
| US20100125070A1 (en) * | 1999-03-01 | 2010-05-20 | Fang Kevin Qun | Bupropion Metabolites and Methods of Their Synthesis and Use |
-
2010
- 2010-05-21 CN CN2010101785769A patent/CN102249951A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4393078A (en) * | 1982-03-15 | 1983-07-12 | Burroughs Wellcome Co. | Bupropion and ethanol |
| US20100125070A1 (en) * | 1999-03-01 | 2010-05-20 | Fang Kevin Qun | Bupropion Metabolites and Methods of Their Synthesis and Use |
| US20070015572A1 (en) * | 2000-10-05 | 2007-01-18 | Igt | Gaming device having a weighted probability for selecting a bonus game |
| US20070155729A1 (en) * | 2006-01-03 | 2007-07-05 | Algebra, Inc. | Therapeutic amine-arylsulfonamide conjugate compounds |
| CN101088985A (en) * | 2007-07-06 | 2007-12-19 | 浙江普洛医药科技有限公司 | Amfebutamone hydrochloride synthesizing process |
Non-Patent Citations (3)
| Title |
|---|
| F. IVY CARROLL等: "Synthesis and Biological Evaluation of Bupropion Analogues as Potential Pharmacotherapies for Cocaine Addiction", 《JOURNAL OF MEDICINAL CHEMISTRY》, no. 52, 12 October 2009 (2009-10-12), pages 6768 - 6781 * |
| F. IVY CARROLL等: "Synthesis and Biological Evaluation of Bupropion Analogues as Potential Pharmacotherapies for Smoking Cessation", 《JOURNAL OF MEDICINAL CHEMISTRY》, no. 53, 16 February 2010 (2010-02-16), pages 2204 - 2214 * |
| SUMA, RAMAGIRI等: "Stability study of bupropion and olanzapine in formaldehyde solutions", 《RAPID COMMUNICATIONS IN MASS SPECTROMETRY》, vol. 20, no. 8, 23 March 2006 (2006-03-23), pages 1390 - 1394 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018168161A (en) | Novel compositions and methods | |
| CN102892288A (en) | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction | |
| US20170072005A1 (en) | Combinations of nmdar modulating compounds | |
| EA200701583A1 (en) | HETEROCYCLIC TETRACYCLIC DERIVATIVES OF HYDROFURANE AS 5HT2 INHIBITORS IN THERAPY OF CNS DISORDERS | |
| TW201924681A (en) | Combination use of KOR agonist and MOR agonist in the preparation of a medicament for the treatment of pain | |
| TWI520949B (en) | Methods of use of cyclic amide derivatives to treat sigma receptor-mediated disorders | |
| JP2009513550A (en) | Ambroxol for the treatment of chronic nociceptive pain | |
| US20190359615A1 (en) | Isoquinoline ether compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| CN102260290A (en) | Quinolinone compounds, and application thereof in preparing antipsychotic drugs | |
| CN110520129A (en) | Delta opiate receptor modulating compound and its use and preparation method containing 5 yuan of aza heterocycles | |
| US20190367506A1 (en) | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| RU2014132428A (en) | A STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION, INCLUDING LEVOCETIRISINE OR ITS PHARMACEUTALLY ACCEPTABLE SALT, AND MONTELUKAST OR ITS PHARMACEUTICAL ACCEPTANCE | |
| Walter | Monoamine reuptake inhibitors: highlights of recent research developments | |
| KR20030053475A (en) | 1-amino-alkylcyclohexanes as 5-ht3 and neuronal nicotinic receptor antagonists | |
| CN105209445B (en) | The method for treating dyskinesia and associated conditions | |
| JP5591310B2 (en) | Novel combination of 4- {3- [cis-hexahydrocyclopenta [c] pyrrol-2 (1H) -yl] propoxy} benzamide and an NMDA receptor antagonist, and pharmaceutical composition comprising the same | |
| CN102249951A (en) | Aminophenyl ketone compound and application thereof in preparing antipsychotic drugs | |
| US11225487B2 (en) | 7-membered aza-heterocyclic containing δ-opioid receptor modulating compounds, methods of using and making the same | |
| CN101796027A (en) | N-piperidin-4-ylmethyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
| EP3324966A1 (en) | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders | |
| CN106243096B (en) | The new application of tricyclic drugs | |
| Shao et al. | Discovery of N-methyl-1-(1-phenylcyclohexyl) ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor | |
| MXPA06000077A (en) | Compositions containing a serotonin selective reuptake inhibitor and a 5-ht2a receptor antagonist. | |
| Stec et al. | Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists | |
| US20170226072A1 (en) | 1,4-Disubstituted Piperidines, 1,4-Disubstituted Piperazines, 1,4-Disubstituted Diazepines, and 1,3-Disubstituted Pyrrolidine Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111123 |